Pregabalin Capsule
Product Images NDC 60760-591

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-591). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-591 (Pregabalin 60760 591 60)

This is a medication label for Pregabalin capsules, in 100mg strength and quantity of 60. The product is manufactured by ScieGen Pharmaceuticals, Inc. and packaged by S, StManys in Arizona. It includes an RX number, but lot numbers and expiration dates are partially obscured. The label instructs users to use as directed and store the medication at room temperature.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

This appears to be a chart indicating the percentage of patients who improved after taking Pregabalin at a dosage of 160mg for three days. The chart also includes numerical values for improvement in pain. However, the chart is not clear and there are some legibility issues with the text.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

This appears to be a record of medication regimens and their effectiveness in improving pain levels for patients. The first section shows the percent of patients who improved with different doses of Pregabalin, while the second section shows the percent improvement in pain from baseline for an unknown medication. No further information is available.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

This is a report on the effectiveness of three medicines - Fregabalin, Pregataiin and Placebo - in improving pain in patients. The doses administered are mentioned as 100 mg of Fregabalin thrice a day, 80 mg of Pregataiin thrice a day and Placebo with unknown dosage. The report contains a chart showing the percentage of patients improved, which is followed by another chart showing the percentage improvement in pain from baseline.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

This is a graph that shows the percentage of patients who improved while taking Pregabalin in doses of 300mg and 450mg per day, compared to a placebo. The X-axis represents the percentage improvement in pain from baseline, while the Y-axis represents the number of patients. There is no additional information available to create a more detailed description.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a table or chart displaying the percentage of subjects without LTR (Long-Term Relapse) over a period of time, with 0-100% listed at intervals of 10%. There are two categories listed, "Progabain" and "Placebo," and a timeline ranging from 0 to 180 days. Not much additional information can be gleaned from this text without further context.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This appears to be a formula for calculating CLCT (creatinine clearance) in a patient based on their age, weight, and serum creatinine levels. The formula involves subtracting the patient's age in years from 140, multiplying that result by the patient's weight in kilograms, then multiplying the product by 0.85 for female patients. The result is then divided by 72 multiplied by the patient's serum creatinine level in milligrams per deciliter.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.